Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years - PubMed (original) (raw)
Clinical Trial
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C Klonoff et al. Curr Med Res Opin. 2008 Jan.
Abstract
Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A(1c) (A1C) and weight in clinical trials. The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety.
Methods: Patients from three placebo-controlled trials and their open-label extensions were enrolled into one open-ended, open-label clinical trial. Patients were randomized to twice daily (BID) placebo, 5 mug exenatide, or 10 mug exenatide for 30 weeks, followed by 5 mug exenatide BID for 4 weeks, then 10 mug exenatide BID for > or = 3 years of exenatide exposure. Patients continued metformin and/or sulfonylureas.
Results: 217 patients (64% male, age 58 +/- 10 years, weight 99 +/- 18 kg, BMI 34 +/- 5 kg/m(2), A1C 8.2 +/- 1.0% [mean +/- SD]) completed 3 years of exenatide exposure. Reductions in A1C from baseline to week 12 (-1.1 +/- 0.1% [mean +/- SEM]) were sustained to 3 years (-1.0 +/- 0.1%; p < 0.0001), with 46% achieving A1C < or = 7%. Exenatide progressively reduced body weight from baseline (-5.3 +/- 0.4 kg at 3 years; p < 0.0001). Patients with elevated serum alanine aminotransferase (ALT) at baseline (n = 116) had reduced ALT (-10.4 +/- 1.5 IU/L; p < 0.0001) and 41% achieved normal ALT. Patients with elevated ALT at baseline tended to lose more weight than patients with normal ALT at baseline (-6.1 +/- 0.6 kg vs. -4.4 +/- 0.5 kg; p = 0.03), however weight change was minimally correlated with baseline ALT (r = -0.01) or ALT change (r = 0.31). Homeostasis Model Assessment B (HOMA-B), blood pressure, and aspartate aminotransferase (AST) all improved. A subset achieved 3.5 years of exenatide exposure and had serum lipids available for analysis (n = 151). Triglycerides decreased 12% (p = 0.0003), total cholesterol decreased 5% (p = 0.0007), LDL-C decreased 6% (p < 0.0001), and HDL-C increased 24% (p < 0.0001). Exenatide was generally well tolerated. The most frequent adverse event was mild-to-moderate nausea. The main limitation of this study is the open-label, uncontrolled nature of the study design which does not provide a placebo group for comparison.
Conclusion: Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
Similar articles
- Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Buse JB, et al. Clin Ther. 2007 Jan;29(1):139-53. doi: 10.1016/j.clinthera.2007.01.015. Clin Ther. 2007. PMID: 17379054 Clinical Trial. - Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Blonde L, et al. Diabetes Obes Metab. 2006 Jul;8(4):436-47. doi: 10.1111/j.1463-1326.2006.00602.x. Diabetes Obes Metab. 2006. PMID: 16776751 Clinical Trial. - Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Sathyanarayana P, et al. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9. Obesity (Silver Spring). 2011. PMID: 21660077 Clinical Trial. - Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Schnabel CA, Wintle M, Kolterman O. Schnabel CA, et al. Vasc Health Risk Manag. 2006;2(1):69-77. doi: 10.2147/vhrm.2006.2.1.69. Vasc Health Risk Manag. 2006. PMID: 17319471 Free PMC article. Review. - Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL, Baker DE, Setter SM, Keith Campbell R. Iltz JL, et al. Clin Ther. 2006 May;28(5):652-65. doi: 10.1016/j.clinthera.2006.05.006. Clin Ther. 2006. PMID: 16861088 Review.
Cited by
- Variants in _PPARD_-GLP1R are related to diabetic kidney disease in Chinese Han patients with type 2 diabetes mellitus.
Song J, Zhuang Y, Pan X, Chen Y, Xie F. Song J, et al. Heliyon. 2024 Jul 26;10(15):e35289. doi: 10.1016/j.heliyon.2024.e35289. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39161836 Free PMC article. - Hepatic glucose metabolism in the steatotic liver.
Scoditti E, Sabatini S, Carli F, Gastaldelli A. Scoditti E, et al. Nat Rev Gastroenterol Hepatol. 2024 May;21(5):319-334. doi: 10.1038/s41575-023-00888-8. Epub 2024 Feb 2. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38308003 Review. - Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia.
Choi SA, Jee HJ, Bormate KJ, Kim Y, Jung YS. Choi SA, et al. Biomol Ther (Seoul). 2023 Nov 1;31(6):583-598. doi: 10.4062/biomolther.2023.115. Biomol Ther (Seoul). 2023. PMID: 37899743 Free PMC article. Review. - Self-reported eating habits and dyslipidemia in men aged 20-39 years: the Japan Environment and Children's Study.
Cui M, Ikehara S, Ueda K, Yamagishi K, Iso H; Japan Environment and Children’s Study Group. Cui M, et al. Environ Health Prev Med. 2023;28:41. doi: 10.1265/ehpm.23-00008. Environ Health Prev Med. 2023. PMID: 37407489 Free PMC article. - Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective.
Pandey S, Mangmool S, Parichatikanond W. Pandey S, et al. Pharmaceuticals (Basel). 2023 Jun 3;16(6):836. doi: 10.3390/ph16060836. Pharmaceuticals (Basel). 2023. PMID: 37375783 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical